|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Al-Sarraf M: Treatment of locally advanced
head and neck cancer: Historical and critical review. Cancer
Control. 9:387–399. 2002.PubMed/NCBI
|
|
3.
|
Seiwert TY and Cohen EEW: State-of-the-art
management of locally advanced head and neck cancer. Br J Cancer.
92:1341–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Urba S, Wolf G, Eisbruch A, Worden F, Lee
J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N and Taylor
J: Single-cycle induction chemotherapy selects patients with
advanced laryngeal cancer for combined chemoradiation: A new
treatment paradigm. J Clin Oncol. 24:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lamonerie T, Tremblay JJ, Lanctôt C,
Therrien M, Gauthier Y and Drouin J: Ptx1, a bicoid-related homeo
box transcription factor involved in transcription of the
pro-opiomelanocortin gene. Genes Dev. 10:1284–1295. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
DeLaurier A, Schweitzer R and Logan M:
Pitx1 determines the morphology of muscle, tendon and bones of the
hindlimb. Dev Biol. 299:22–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kolfschoten IGM, van Leeuwen B, Berns K,
Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami
R: A genetic screen identifies PITX1 as a suppressor of RAS
activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Qi DL, Ohhira T, Fujisaki C, Inoue T, Ohta
T, Osaki M, Ohshiro E, Seko T, Aoki S, Oshimura M and Kugoh H:
Identification of PITX1 as a TERT suppressor gene located on human
chromosome 5. Mol Cell Biol. 31:1624–1636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Libório TN, Acquafreda T,
Matizonkas-Antonio LF, Silva-Valenzuela MG, Ferraz AR and Nunes FD:
In situ hybridization detection of homeobox genes reveals distinct
expression patterns in oral squamous cell carcinomas.
Histopathology. 58:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Osaki M, Chinen H, Yoshida Y, Ohhira T,
Sunamura N, Yamamoto O, Ito H, Oshimura M and Kugoh H: Decreased
PITX1 gene expression in human cutaneous malignant melanoma and its
clinicopathological significance. Eur J Dermatol. 23:344–349.
2013.PubMed/NCBI
|
|
11.
|
Lord RV, Brabender J, Wickramasinghe K,
DeMeester SR, Holscher A, Schneider PM, Danenberg PV and DeMeester
TR: Increased CDX2 and decreased PITX1 homeobox gene expression in
Barrett's esophagus and Barrett's-associated adenocarcinoma.
Surgery. 138:924–931. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chen YN, Chen H, Xu Y, Zhang X and Luo Y:
Expression of pituitary homeobox 1 gene in human gastric
carcinogenesis and its clinicopathological significance. World J
Gastroenterol. 14:292–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Chen Y, Knösel T, Ye F, Pacyna-Gengelbach
M, Deutschmann N and Petersen I: Decreased PITX1 homeobox gene
expression in human lung cancer. Lung Cancer. 55:287–294. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Stender JD, Stossi F, Funk CC, Charn TH,
Barnett DH and Katzenellenbogen BS: The estrogen-regulated
transcription factor PITX1 coordinates gene-specific regulation by
estrogen receptor-alpha in breast cancer cells. Mol Endocrinol.
25:1699–1709. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Calvisi DF, Ladu S, Conner EA, Seo D,
Hsieh JT, Factor VM and Thorgeirsson SS: Inactivation of Ras
GTPase-activating proteins promotes unrestrained activity of
wild-type Ras in human liver cancer. J Hepatol. 54:311–319. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Knösel T, Chen Y, Hotovy S, Settmacher U,
Altendorf-Hofmann A and Petersen I: Loss of desmocollin 1–3 and
homeobox genes PITX1 and CDX2 are associated with tumor progression
and survival in colorectal carcinoma. Int J Colorectal Dis.
27:1391–1399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kwok SC, Liu XM, Mangel P and Daskal I:
PTX1 (ERGIC2)-VP22 fusion protein upregulates interferon-beta in
prostate cancer cell line PC-3. DNA Cell Biol. 25:523–529. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Somers KD, Merrick MA, Lopez ME, Incognito
LS, Schechter GL and Casey G: Frequent p53 mutations in head and
neck cancer. Cancer Res. 52:5997–6000. 1992.PubMed/NCBI
|
|
19.
|
Poeta M, Manola J, Goldwasser MA,
Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D,
Saunders J, et al: TP53 mutations and survival in squamous-cell
carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Warnakulasuriya S, Jia C, Johnson N and
Houghton J: p53 and P-glycoprotein expression are significant
prognostic markers in advanced head and neck cancer treated with
chemo/radiotherapy. J Pathol. 191:33–38. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Mannarini L, Bertino G, Morbini P, Villa C
and Benazzo M: Markers of chemoradiation resistance in patients
with locally advanced head and neck squamous cell carcinoma,
treated by intra-arterial carboplatin and concurrent radiation.
Acta Otorhinolaryngol Ital. 27:173–180. 2007.PubMed/NCBI
|
|
22.
|
Temam S, Flahault A, Périé S, Monceaux G,
Coulet F, Callard P, Bernaudin JF, St Guily JL and Fouret P: P53
gene status as a predictor of tumor response to induction
chemotherapy of patients with locoregionally advanced squamous cell
carcinomas of the head and neck. J Clin Oncol. 18:385–394.
2000.PubMed/NCBI
|
|
23.
|
Okumura K, Hasegawa Y, Harada H, Ishizaki
K and Murakami S: A comparative study of p53 status and clinical
response to chemotherapy in head and neck cancer. Nagoya Med J.
46:171–180. 2003.
|
|
24.
|
Szentkúti G, Dános K, Brauswetter D,
Kiszner G, Krenács T, Csákó L, Répássy G and Tamás L: Correlations
between prognosis and regional biomarker profiles in head and neck
squamous cell carcinomas. Pathol Oncol Res. 21:643–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweji J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guldelines to
evaluate the response to treatment in solod tumors. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Nakashima T, Maehara Y, Kohnoe S, Hayashi
I and Katsuta Y: Histologic differentiation and chemosensitivity of
human head and neck squamous cell carcinomas. Head Neck.
12:406–410. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Hoffmann TK, Sonkoly E, Hauser U, van
Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P,
Friebe-Hoffmann U, Scheckenbach K, et al: Alterations in the p53
pathway and their association with radio- and chemosensitivity in
head and neck squamous cell carcinoma. Oral Oncol. 44:1100–1109.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hoa M, Davis SL, Ames SJ and Spanjaard RA:
Amplification of wild-type K -ras promotes growth of head and neck
squamous. Cancer Res. 62:7154–7156. 2002.PubMed/NCBI
|
|
29.
|
Blagoev KB: Cell proliferation in the
presence of telomerase. PLoS One. 4:e46222009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ohira T, Naohiro S, Nakayama Y, Osaki M,
Okada F, Oshimura M and Kugoh H: miR-19b regulates hTERT mRNA
expression through targeting PITX1 mRNA in melanoma cells. Sci Rep.
5:82012015. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ueda Y, Hiyama E, Kamimatsuse A, Kamei N,
Ogura K and Sueda T: Wnt signaling and telomerase activation of
hepatoblastoma: Correlation with chemosensitivity and surgical
resectability. J Pediatr Surg. 46:2221–2227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Wang L, Li PF, Geng M, Cao YC and Yin YC:
Correlation between chemosensitivity to anticancer drugs and
telomerase reverse transcriptase mRNA expression in gastric cancer.
Diagn Pathol. 8:332013. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Guo X, Wang W, Zhou F, Lu Z, Fang R, Jia
F, Bu X, Li R, Zhang B, Wu M and Wei L: siRNA-mediated inhibition
of hTERT enhances chemosensitivity of hepatocellular carcinoma.
Cancer Biol Ther. 7:1555–1560. 2008. View Article : Google Scholar : PubMed/NCBI
|
